Sarepta To Pay $35M Plus Royalties In Exondys Patent Dispute
Sarepta Therapeutics Inc. said Tuesday it has agreed to shell out $35 million plus royalties and payments for additional regulatory and commercial milestones to end a patent fight with BioMarin Pharmaceutical...To view the full article, register now.
Already a subscriber? Click here to view full article